Vesicular stomatitis virus:: An exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?.

被引：21

作者：

Giedlin, MA ^{[1
]}

Cook, DN ^{[1
]}

Dubensky, TW ^{[1
]}

机构：

[1] Cerus Corp, Canc Res, Concord, CA 94520 USA

来源：

CANCER CELL | 2003年 / 4卷 / 04期

关键词：

D O I：

10.1016/S1535-6108(03)00251-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Selected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to combat endogenous IFN-beta signaling within infected normal cells and as a result are dramatically more selective for productive growth in tumor cells having a defective antiviral response. The VSV mutants may have the potential to be used clinically as a systemic oncolytic agent for the treatment of distal and metastatic cancers.

引用

页码：241 / 243

页数：3

共 12 条

[1] Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection
Balachandran, S
Roberts, PC
Brown, LE
Truong, H
Pattnaik, AK
Archer, DR
Barber, GN
[J]. IMMUNITY, 2000, 13 (01) : 129 - 141
[2] Vesicular stomatitis virus (VSV) therapy of tumors
Balachandran, S
Barber, GN
[J]. IUBMB LIFE, 2000, 50 (02) : 135 - 138
[3] VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum
DePolo, NJ
Reed, JD
Sheridan, PL
Townsend, K
Sauter, SL
Jolly, DJ
Dubensky, TW
[J]. MOLECULAR THERAPY, 2000, 2 (03) : 218 - 222
[4] Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells
Desforges, M
Charron, J
Bérard, S
Beausoleil, S
Stojdl, DF
Despars, G
Laverdière, B
Bell, JC
Talbot, PJ
Stanners, CP
Poliquin, L
[J]. VIRUS RESEARCH, 2001, 76 (01) : 87 - 102
[5] Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice
Huang, TG
Ebert, O
Shinozaki, K
García-Sastre, A
Woo, SLC
[J]. MOLECULAR THERAPY, 2003, 8 (03) : 434 - 440
[6] Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
Kirn, D
Martuza, RL
Zwiebel, J
[J]. NATURE MEDICINE, 2001, 7 (07) : 781 - 787
[7] Innate recognition of bacteria by a macrophage cytosolic surveillance pathway
O'Riordan, M
Yi, CH
Gonzales, R
Lee, KD
Portnoy, DA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) : 13861 - 13866
[8] Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity
Obuchi, M
Fernandez, M
Barber, GN
[J]. JOURNAL OF VIROLOGY, 2003, 77 (16) : 8843 - 8856
[9] The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes
Petersen, JM
Her, LS
Varvel, V
Lund, E
Dahlberg, JE
[J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (22) : 8590 - 8601
[10] RNA viruses as virotherapy agents
Russell, SJ
[J]. CANCER GENE THERAPY, 2002, 9 (12) : 961 - 966

← 1 2 →